Dr. Haseebuddin on PD-1 Expression on Monocytes in RCC

Mohammed Haseebuddin, MD
Published: Thursday, Jul 21, 2016


Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discusses the overall significance of a study examining an elevated preoperative classical monocyte PD-1 mean fluorescence intensity level in patients with clear cell renal cell carcinoma (RCC).

There are 3 different types of monocytes, Haseebuddin explains, which are classical, intermediate, and non-classical. It is thought that the classical monocytes resemble proinflammatory monocytes, which then enter the tissue and act against cancer. All 3 of these monocytes play a role, he adds.

Regarding this study, researchers believed that PD-1 expression in select patient populations affects survival, leading to the idea that if monocytes seem to play a central role in the immune system, then perhaps PD-1 expression on monocytes are important for survival.

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discusses the overall significance of a study examining an elevated preoperative classical monocyte PD-1 mean fluorescence intensity level in patients with clear cell renal cell carcinoma (RCC).

There are 3 different types of monocytes, Haseebuddin explains, which are classical, intermediate, and non-classical. It is thought that the classical monocytes resemble proinflammatory monocytes, which then enter the tissue and act against cancer. All 3 of these monocytes play a role, he adds.

Regarding this study, researchers believed that PD-1 expression in select patient populations affects survival, leading to the idea that if monocytes seem to play a central role in the immune system, then perhaps PD-1 expression on monocytes are important for survival.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x